2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic
Forward signals for 2026—from >$1.3B in tracked financings led by Neuralink’s $650M round to a shoebox-sized biocomputer, driven device control, speech restoration, and early clinical proof points.
As we step into 2026, let’s look back at how neurotech unfolded over the past year. In 2025, neurotechnology broadened and sped up across multiple fronts. BCIs, brain-targeted delivery, neurodiagnostics, organoids, and neuro-focused AI all saw more activity moving from concept work into larger studies, bigger datasets, and concrete development plans, with sizable Series A-D rounds backing specific bets on CNS biology.
Read this Pro article free
Subscribe to BiopharmaTrend Insider, our free biweekly briefing on what matters in tech and bio, and get one free Pro article every month, starting with this one.
Insider arrives every two weeks, plus a short note when we publish a new deep dive. Unsubscribe anytime. Articles you unlock stay unlocked.